Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.5K Buy
2,631
+882
+50% +$9.8K ﹤0.01% 6772
2026
Q2
$18K Sell
1,749
-11,467
-87% -$86.6K ﹤0.01% 7197
2026
Q1
$64.8K Buy
+13,216
New +$71.9K ﹤0.01% 5576
2025
Q2
– Sell
-17,107
Closed -$88K – 8692
2025
Q1
$96K Buy
17,107
+12,538
+274% +$102K ﹤0.01% 5093
2024
Q4
$39K Sell
4,569
-18,269
-80% -$108K ﹤0.01% 6108
2024
Q3
$158K Buy
22,838
+17,837
+357% +$111K ﹤0.01% 4755
2024
Q2
$31K Buy
+5,001
New +$37.5K ﹤0.01% 6523

Other funds holding CADL

Simplex Trading's CADL Position: Q3 2026 in Review

Simplex Trading increased its Candel Therapeutics (CADL) stake by 50% in Q3 2026, buying an estimated $9.8K and bringing the position to 2,631 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6772.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 7 quarters since. The position peaked at $158K in Q3 2024. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Simplex Trading held 2,631 shares of Candel Therapeutics worth $27.5K as of Q3 2026.
  • Simplex Trading bought 882 Candel Therapeutics shares in Q3 2026, an estimated $9.8K.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #6772 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.